Peptides for inhibiting angiogenesis
The present invention relates to peptides for inhibiting angiogenesis. The present invention also relates to methods of inhibiting angiogenesis and methods of treating disorders associated with VEGF-induced vascular permeability using the peptides of the invention.
1. A method of inhibiting angiogenesis comprising administering to a patient in need thereof an isolated peptide comprising the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1) or FTEIPTI (SEQ ID NO: 3), wherein the patient is suffering from cancer, visual impairment, vision loss (blindness), macular degeneration, central retinal vein occlusion, branch retinal vein occlusion proliferative diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina ischemia, diabetic retinal edema, and proliferative diabetic retinopathy, rubeosis iridis, neovascular glaucoma, retinoblastoma, uveitis or corneal graft neovascularization.
2. The method of claim 1 , wherein the isolated peptide is administered by intravitreal injection or topically.
3. The method of claim 1 , wherein the peptide is linked to a carrier peptide.
4. The method of claim 3 , wherein the carrier peptide is antennapedia peptide (AP), penetratin peptide, TAT, tranportan or polyarginine.
5. The method of claim 1 , wherein the peptide is conjugated to a fatty acid.
6. The method of claim 5 , wherein the peptide is myrisoylated.
7. The method of claim 1 , wherein the isolated peptide is administered in combination with one or more VEGF inhibitors.
8. The method of claim 1 , wherein the isolated peptide is administered in combination with laser treatment of eye disease.
9. The method of claim 1 , wherein the isolated peptide is administered in combination with a steroid.
10. A method of treating a disorder associated with VEGF-induced vascular permeability comprising administering to a patient in need thereof an isolated peptide comprising the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1) or FTEIPTI (SEQ ID NO: 3), wherein the disorder is cancer, visual impairment, vision loss (blindness), macular degeneration, central retinal vein occlusion, branch retinal vein occlusion proliferative diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina ischemia, diabetic retinal edema, and proliferative diabetic retinopathy, rubeosis iridis, neovascular glaucoma, retinoblastoma, uveitis or corneal graft neovascularization.
11. The method of claim 10 , wherein the isolated peptide is administered by intravitreal injection or topically.
12. The method of claim 10 , wherein the peptide is linked to a carrier peptide.
13. The method of claim 12 , wherein the carrier peptide is antennapedia peptide (AP), antennapedia peptide, penetratin peptide, TAT, tranportan or polyarginine.
14. The method of claim 10 , wherein the peptide is conjugated to a fatty acid.
15. The method of claim 14 , wherein the peptide is myrisoylated.
16. The method of claim 10 , wherein the isolated peptide is administered in combination with one or more VEGF inhibitors.
17. The method of claim 10 , wherein the isolated peptide is administered in combination with laser treatment of eye disease.
18. The method of claim 10 , wherein the isolated peptide is administered in combination with a steroid.